FILE COVERS 1907 - 7 May 2004 VOL 140 ISS 20
FILE LAST UPDATED: 6 May 2004 (20040506/ED)

This file contains CAS Registry Numbers for easy and accurate substance identification.

=> s l2
L3 4 L2

=> d l3 1-4 ibib abs hitstr

L3 ANSWER 1 OF 4 CAPLUS COPYRIGHT 2004 ACS on STN
ACCESSION NUMBER: 2003:875294 CAPLUS
DOCUMENT NUMBER: 139:364955
TITLE: Preparation of triaryl-oxy-aryl-spiro-pyrimidinetrione metalloproteinase inhibitors selective towards MMP-13
INVENTOR(S): Freeman-cook, Kevin Daniel; Noe, Mark Carl
PATENT ASSIGNEE(S): Pfizer Products Inc., USA
SOURCE: PCT Int. Appl., 92 pp.
CODEN: PIXXD2
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2003091259	A1	20031106	WO 2003-IB1576	20030415
WO 2003091259	C1	20040212		
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, OM, PH, PL, PT, RO, RU, SD, SE, SG, SK, SL, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM				
RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				
US 2003225056	A1	20031204	US 2003-423671	20030425

PRIORITY APPLN. INFO.: US 2002-376157P P 20020426
OTHER SOURCE(S): MARPAT 139:364955
GI

10/423,671
obv dp

* STRUCTURE DIAGRAM TOO LARGE FOR DISPLAY - AVAILABLE VIA OFFLINE PRINT *

AB The present invention relates to triaryl-oxy-aryl-spiro-pyrimidinetrione metalloproteinase inhibitors (shown as I; variables defined below; e.g. II) and to pharmaceutical compns. and methods of treating inflammation, cancer and other disorders. For I: ; ring X is a 5-7 membered heterocyclic ring; A is (C6-C10)aryl or (C1-C10)heteroaryl; Y = a bond, -O-, -S-, >C:O, >SO2, >S:O, -CH2O-, -OCH2-, -CH2S-, -SCH2-, -CH2SO-, -CH2SO2-, -SOCH2-, -SO2CH2-, >NR14, -[N(R14)]CH2-, -CH2[N(R14)]-, -CH2-, -CH:CH-, -C.tplbond.C-, -[N(R14)]SO2- and -SO2[N(R14)]-; B is (C6-C10)aryl, (C3-C7)cycloalkyl, (C1-C10)heterocyclyl and (C1-C10)heteroaryl; G is -R15(CR16R17)p-; p = 0-4; W is (C1-C4)alkoxy(C1-C4)alkyl, (C3-C7)cycloalkyl, (C6-C10)aryl, (C1-C10)heteroaryl and (C1-C10)heterocyclyl; addnl. details including provisos are given in the claims. General semiquant. statements are made about inhibition of metalloproteinases by I; no data is presented for specific examples of I; some I exhibit selectivity towards MMP-13 relative to other metalloproteinases but they are not identified. Although the methods of preparation are not claimed, example prepns. of 5 I are included.

IT **620971-38-2P**, 1-[6-[4-[4-(4-Fluorophenyl)oxazol-2-yl]phenoxy]pyridin-3-yl]-1,7,9-triazaspiro[4.5]decane-6,8,10-trione **620971-44-0P**, 4-[2-[4-[[5-(6,8,10-Trioxo-1,7,9-triazaspiro[4.5]dec-1-yl)pyridin-2-yl]oxy]phenyl]oxazol-4-yl]benzonitrile **620971-47-3P**, 3-[2-[4-[[5-(6,8,10-Trioxo-1,7,9-triazaspiro[4.5]dec-1-yl)pyridin-2-yl]oxy]phenyl]oxazol-4-yl]benzonitrile **620971-50-8P**, 1-[6-[4-[4-(2-Fluorophenyl)oxazol-2-yl]phenoxy]pyridin-3-yl]-1,7,9-triazaspiro[4.5]decane-6,8,10-trione **620971-52-0P**, 1-[6-[4-[4-(3-Fluorophenyl)oxazol-2-yl]phenoxy]pyridin-3-yl]-1,7,9-triazaspiro[4.5]decane-6,8,10-trione
RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(drug candidate; preparation of triaryl-oxy-aryl-spiro-pyrimidinetrione metalloproteinase inhibitors selective towards MMP-13)

RN 620971-38-2 CAPLUS

CN 1,7,9-Triazaspiro[4.5]decane-6,8,10-trione, 1-[6-[4-[4-(4-fluorophenyl)-2-oxazolyl]phenoxy]-3-pyridinyl]- (9CI) (CA INDEX NAME)





PAGE 1-A



PAGE 2-A

RN 620971-44-0 CAPLUS
CN Benzonitrile, 4-[2-[4-[[5-(6,8,10-trioxo-1,7,9-triazaspiro[4.5]dec-1-yl)-2-pyridinyl]oxy]phenyl]-4-oxazolyl]- (9CI) (CA INDEX NAME)

PAGE 1-A



PAGE 2-A



RN 620971-47-3 CAPLUS
CN Benzonitrile, 3-[2-[4-[[5-(6,8,10-trioxo-1,7,9-triazaspiro[4.5]dec-1-yl)-2-pyridinyl]oxy]phenyl]-4-oxazolyl]- (9CI) (CA INDEX NAME)

PAGE 1-A



PAGE 2-A



RN 620971-50-8 CAPLUS
CN 1,7,9-Triazaspiro[4.5]decane-6,8,10-trione, 1-[6-[4-[4-(2-fluorophenyl)-2-oxazolyl]phenoxy]-3-pyridinyl]- (9CI) (CA INDEX NAME)

PAGE 1-A



PAGE 2-A



RN 620971-52-0 CAPLUS
CN 1,7,9-Triazaspiro[4.5]decane-6,8,10-trione, 1-[6-[4-[4-(3-fluorophenyl)-2-oxazolyl]phenoxy]-3-pyridinyl]- (9CI) (CA INDEX NAME)

PAGE 1-A



PAGE 2-A



REFERENCE COUNT: 2 THERE ARE 2 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L3 ANSWER 2 OF 4 CAPLUS COPYRIGHT 2004 ACS on STN
ACCESSION NUMBER: 2003:875293 CAPLUS
DOCUMENT NUMBER: 139:364954
TITLE: Preparation of N-substituted-heteroaryloxy-aryl-spiro-pyrimidinetrione metalloproteinase inhibitors selective towards MMP-13
INVENTOR(S): Noe, Mark Carl; Freeman-cook, Kevin Daniel
PATENT ASSIGNEE(S): Pfizer Products Inc., USA
SOURCE: PCT Int. Appl., 86 pp.
CODEN: PIXXD2
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2003091258	A1	20031106	WO 2003-IB1508	20030415

W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, OM, PH, PL, PT, RO, RU, SD, SE, SG, SK, SL, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM
RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG

US 2004010141 A1 20040115 US 2003-423779 20030425
PRIORITY APPLN. INFO.: US 2002-376159P P 20020426
OTHER SOURCE(S): MARPAT 139:364954
GI

10/423,779

* STRUCTURE DIAGRAM TOO LARGE FOR DISPLAY - AVAILABLE VIA OFFLINE PRINT *

AB The present invention relates to N-substituted-heteroaryloxy-aryl-spiro-pyrimidine-2,4,6-trione metalloproteinase inhibitors (shown as I; variables defined below; e.g. II) and to pharmaceutical compns. and methods of treating inflammation, cancer and other disorders. For I: ; ring X is a 5-7 membered heterocyclic ring; A is (C6-C10)aryl or (C2-C10)heteroaryl; Y = a bond, -O-, -S-, >C:O, >SO2, >S:O, -CH2O-, -OCH2-, -CH2S-, -SCH2-, -CH2SO-, -CH2SO2-, -SOCH2-, -SO2CH2-, >NR14, -[N(R14)]CH2-, -CH2[N(R14)]-, -CH2-, -CH:CH-, -C.tplbond.C-, -[N(R14)]SO2- and -SO2[N(R14)]-; B is a heterocyclyl containing at least one N atom; wherein one ring N atom of B is bonded to one C atom of G; G is (C1-C6)alkyl or R15-(CR16R17)p-; p = 0-4; addnl. details including provisos are given in the claims. General semiquant. statements are made about inhibition of metalloproteinases by I; no data is presented for specific examples of I; some I exhibit selectivity towards MMP-13 relative to other metalloproteinases but they are not identified. Although the methods of preparation are not claimed, example prepns. of 4 I are included.

IT **620965-06-2P**, 1-[6-[[1-(4-Fluorophenyl)-1H-indazol-5-yl]oxy]pyridin-3-yl]-1,7,9-triazaspiro[4.5]decane-6,8,10-trione **620965-13-1P**, 4-[5-[[5-(6,8,10-Trioxo-1,7,9-triazaspiro[4.5]dec-1-yl)pyridin-2-yl]oxy]indazol-1-yl]benzonitrile **620965-19-7P**, 1-[6-[[1-(Pyridin-3-yl)-1H-indazol-5-yl]oxy]pyridin-3-yl]-1,7,9-triazaspiro[4.5]decane-6,8,10-trione **620965-26-6P**, 1-[6-[(1-Methyl-1H-indazol-5-yl)oxy]pyridin-3-yl]-1,7,9-triazaspiro[4.5]decane-6,8,10-trione **620965-33-5P**, 1-[6-[(1-Isopropyl-1H-indazol-5-yl)oxy]pyridin-3-yl]-1,7,9-triazaspiro[4.5]decane-6,8,10-trione **620965-35-7P**, 1-[6-[(2-Isopropyl-2H-indazol-5-yl)oxy]pyridin-3-yl]-1,7,9-triazaspiro[4.5]decane-6,8,10-trione **620965-36-8P**, 4-[5-[[5-(6,8,10-Trioxo-1,7,9-triazaspiro[4.5]dec-1-yl)pyridin-2-yl]oxy]indazol-2-yl]benzonitrile **620965-38-0P**, 1-[6-[[2-(2-Hydroxyethyl)-1-oxo-2,3-dihydro-1H-isoindol-5-yl]oxy]pyridin-3-yl]-1,7,9-triazaspiro[4.5]decane-6,8,10-trione **620965-39-1P**, 1-[6-[[2-(2-Ethoxyethyl)-1-oxo-2,3-dihydro-1H-isoindol-5-yl]oxy]pyridin-3-yl]-1,7,9-triazaspiro[4.5]decane-6,8,10-trione **620965-40-4P**, 1-[6-[[2-(4-Fluorophenyl)-1,2,3,4-tetrahydroisoquinolin-6-yl]oxy]pyridin-3-yl]-1,7,9-triazaspiro[4.5]decane-6,8,10-trione **620965-41-5P**, 1-[6-[[1-(4-Fluorophenyl)-1,2,3,4-tetrahydroquinolin-6-yl]oxy]pyridin-3-yl]-1,7,9-triazaspiro[4.5]decane-6,8,10-trione **620965-42-6P**, 1-[6-[[1-(4-Fluorophenyl)-2,3-dihydro-1H-indol-5-yl]oxy]pyridin-3-yl]-1,7,9-triazaspiro[4.5]decane-6,8,10-trione **620965-43-7P**,

1-[6-[[2-(Pyridin-3-yl)-2H-indazol-5-yl]oxy]pyridin-3-yl]-1,7,9-triazaspiro[4.5]decane-6,8,10-trione **620965-44-8P**, 1-[6-[[2-(4-Fluorophenyl)-2,3-dihydro-1H-isoindol-5-yl]oxy]pyridin-3-yl]-1,7,9-triazaspiro[4.5]decane-6,8,10-trione **620965-45-9P**, 1-[6-[[1-(Pyridin-3-yl)-2,3-dihydro-1H-indol-5-yl]oxy]pyridin-3-yl]-1,7,9-triazaspiro[4.5]decane-6,8,10-trione **620965-46-0P**, 1-[6-[[2-(4-Fluorophenyl)-2H-indazol-5-yl]oxy]pyridin-3-yl]-1,7,9-triazaspiro[4.5]decane-6,8,10-trione **620965-47-1P**, 1-[6-[[1-(4-Fluorophenyl)-2,3,4,5-tetrahydro-1H-benzo[b]azepin-7-yl]oxy]pyridin-3-yl]-1,7,9-triazaspiro[4.5]decane-6,8,10-trione **620965-48-2P**, 1-[6-[[1-(4-Fluorophenyl)-1H-benzimidazol-5-yl]oxy]pyridin-3-yl]-1,7,9-triazaspiro[4.5]decane-6,8,10-trione **620965-49-3P**, 6-[7-[[5-(6,8,10-Trioxo-1,7,9-triazaspiro[4.5]dec-1-yl)pyridin-2-yl]oxy]-2,3,4,5-tetrahydrobenzo[b]azepin-1-yl]nicotinonitrile **620965-50-6P**, 6-[5-[[5-(6,8,10-Trioxo-1,7,9-triazaspiro[4.5]dec-1-yl)pyridin-2-yl]oxy]-2,3-dihydroindol-1-yl]nicotinonitrile **620965-51-7P**, 1-[6-[[2-(Pyridin-3-yl)-2,3-dihydro-1H-isoindol-5-yl]oxy]pyridin-3-yl]-1,7,9-triazaspiro[4.5]decane-6,8,10-trione **620965-52-8P**, 6-[6-[[5-(6,8,10-Trioxo-1,7,9-triazaspiro[4.5]dec-1-yl)pyridin-2-yl]oxy]-3,4-dihydro-2H-quinolin-1-yl]nicotinonitrile **620965-53-9P**, 1-[6-[[1-(Pyridin-4-yl)-2,3,4,5-tetrahydro-1H-benzo[b]azepin-7-yl]oxy]pyridin-3-yl]-1,7,9-triazaspiro[4.5]decane-6,8,10-trione **620965-54-0P**, 1-[6-[[1-(Pyridin-3-yl)-2,3,4,5-tetrahydro-1H-benzo[b]azepin-7-yl]oxy]pyridin-3-yl]-1,7,9-triazaspiro[4.5]decane-6,8,10-trione **620965-55-1P**, 6-[6-[[5-(6,8,10-Trioxo-1,7,9-triazaspiro[4.5]dec-1-yl)pyridin-2-yl]oxy]-3,4-dihydro-1H-isoquinolin-2-yl]nicotinonitrile **620965-56-2P**, 6-[5-[[5-(6,8,10-Trioxo-1,7,9-triazaspiro[4.5]dec-1-yl)pyridin-2-yl]oxy]-1,3-dihydroisoindol-2-yl]nicotinonitrile **620965-57-3P**, 6-[5-[[5-(6,8,10-Trioxo-1,7,9-triazaspiro[4.5]dec-1-yl)pyridin-2-yl]oxy]indazol-1-yl]nicotinonitrile **620965-58-4P**, 6-[5-[[5-(6,8,10-Trioxo-1,7,9-triazaspiro[4.5]dec-1-yl)pyridin-2-yl]oxy]indazol-2-yl]nicotinonitrile **620965-59-5P**, 1-[6-[[2-(Pyridin-4-yl)-2,3-dihydro-1H-isoindol-5-yl]oxy]pyridin-3-yl]-1,7,9-triazaspiro[4.5]decane-6,8,10-trione **620965-60-8P**, 1-[6-[[1-(Pyridin-4-yl)-1H-benzimidazol-5-yl]oxy]pyridin-3-yl]-1,7,9-triazaspiro[4.5]decane-6,8,10-trione **620965-61-9P**, 1-[6-[[2-(Pyridin-4-yl)-1,2,3,4-tetrahydroisoquinolin-6-yl]oxy]pyridin-3-yl]-1,7,9-triazaspiro[4.5]decane-6,8,10-trione **620965-62-0P**, 1-[6-[[2-(Pyridin-3-yl)-1,2,3,4-tetrahydroisoquinolin-6-yl]oxy]pyridin-3-yl]-1,7,9-triazaspiro[4.5]decane-6,8,10-trione **620965-63-1P**, 1-[6-[[1-(Pyridin-4-yl)-2,3-dihydro-1H-indol-5-yl]oxy]pyridin-3-yl]-1,7,9-triazaspiro[4.5]decane-6,8,10-trione **620965-64-2P**, 1-[6-[[1-(Pyridin-4-yl)-1H-indazol-5-yl]oxy]pyridin-3-yl]-1,7,9-triazaspiro[4.5]decane-6,8,10-trione **620965-65-3P**, 1-[6-[[1-(Pyridin-3-yl)-1H-benzimidazol-5-yl]oxy]pyridin-3-yl]-1,7,9-triazaspiro[4.5]decane-6,8,10-trione **620965-66-4P**, 1-[6-[[1-(Pyridin-4-yl)-1,2,3,4-tetrahydroquinolin-6-yl]oxy]pyridin-3-yl]-1,7,9-triazaspiro[4.5]decane-6,8,10-trione **620965-67-5P**, 1-[6-[[2-(Pyridin-4-yl)-2H-indazol-5-yl]oxy]pyridin-3-yl]-1,7,9-triazaspiro[4.5]decane-6,8,10-trione **620965-68-6P**, 1-[6-[[1-(Pyridin-3-yl)-1,2,3,4-tetrahydroquinolin-6-yl]oxy]pyridin-3-yl]-1,7,9-triazaspiro[4.5]decane-6,8,10-trione **620965-69-7P**, 1-[6-[[2-(p-Tolyl)-2H-indazol-5-yl]oxy]pyridin-3-yl]-1,7,9-triazaspiro[4.5]decane-6,8,10-trione **620965-70-0P**, 1-[6-[[2-(p-Tolyl)-2,3-dihydro-1H-isoindol-5-yl]oxy]pyridin-3-yl]-1,7,9-triazaspiro[4.5]decane-6,8,10-trione **620965-71-1P**, 1-[6-[[2-(4-Chlorophenyl)-2H-indazol-5-yl]oxy]pyridin-3-yl]-1,7,9-triazaspiro[4.5]decane-6,8,10-trione **620965-72-2P**, 1-[6-[[2-(4-Chlorophenyl)-2,3-dihydro-1H-isoindol-5-yl]oxy]pyridin-3-yl]-1,7,9-triazaspiro[4.5]decane-6,8,10-trione **620965-73-3P**,

1-[6-[[2-(Pyridin-2-yl)-2H-indazol-5-yl]oxy]pyridin-3-yl]-1,7,9-triazaspiro[4.5]decane-6,8,10-trione **620965-74-4P**, 1-[6-[[2-(Pyridin-2-yl)-2,3-dihydro-1H-isoindol-5-yl]oxy]pyridin-3-yl]-1,7,9-triazaspiro[4.5]decane-6,8,10-trione **620965-75-5P**, 1-[6-[[2-(3-Methoxypropyl)-2H-indazol-5-yl]oxy]pyridin-3-yl]-1,7,9-triazaspiro[4.5]decane-6,8,10-trione **620965-76-6P**, 1-[6-[[2-(Pyridazin-3-yl)-2H-indazol-5-yl]oxy]pyridin-3-yl]-1,7,9-triazaspiro[4.5]decane-6,8,10-trione **620965-77-7P**, 1-[6-[(1-Isopropyl-2,3-dihydro-1H-indol-5-yl)oxy]pyridin-3-yl]-1,7,9-triazaspiro[4.5]decane-6,8,10-trione **620965-78-8P**, 1-[6-[(1-Isopropyl-1H-benzimidazol-5-yl)oxy]pyridin-3-yl]-1,7,9-triazaspiro[4.5]decane-6,8,10-trione **620965-79-9P**, 1-[6-[(2-Isopropyl-2,3-dihydro-1H-isoindol-5-yl)oxy]pyridin-3-yl]-1,7,9-triazaspiro[4.5]decane-6,8,10-trione **620965-80-2P**, 1-[6-[[2-(Pyridin-2-yl)-1,2,3,4-tetrahydroisoquinolin-6-yl]oxy]pyridin-3-yl]-1,7,9-triazaspiro[4.5]decane-6,8,10-trione **620965-81-3P**, 1-[6-[[2-(Pyridazin-3-yl)-1,2,3,4-tetrahydroisoquinolin-6-yl]oxy]pyridin-3-yl]-1,7,9-triazaspiro[4.5]decane-6,8,10-trione **620965-82-4P**, 1-[6-[(2-Isopropyl-1,2,3,4-tetrahydroisoquinolin-6-yl)oxy]pyridin-3-yl]-1,7,9-triazaspiro[4.5]decane-6,8,10-trione **620965-83-5P**, 1-[6-[[2-(Pyridazin-3-yl)-2,3-dihydro-1H-isoindol-5-yl]oxy]pyridin-3-yl]-1,7,9-triazaspiro[4.5]decane-6,8,10-trione **620965-84-6P**, 1-[6-[[2-(3-Methoxypropyl)-2,3-dihydro-1H-isoindol-5-yl]oxy]pyridin-3-yl]-1,7,9-triazaspiro[4.5]decane-6,8,10-trione **620965-85-7P**, 1-[6-[[2-(3-Methoxypropyl)-1,2,3,4-tetrahydroisoquinolin-6-yl]oxy]pyridin-3-yl]-1,7,9-triazaspiro[4.5]decane-6,8,10-trione **620965-86-8P**, 1-[6-[[2-(4-Methoxyphenyl)-2H-indazol-5-yl]oxy]pyridin-3-yl]-1,7,9-triazaspiro[4.5]decane-6,8,10-trione **620965-87-9P**, 1-[6-[(1-Isopropyl-1,2,3,4-tetrahydroquinolin-6-yl)oxy]pyridin-3-yl]-1,7,9-triazaspiro[4.5]decane-6,8,10-trione **620965-88-0P**, 1-[6-[[1-(3-Methoxypropyl)-1,2,3,4-tetrahydroquinolin-6-yl]oxy]pyridin-3-yl]-1,7,9-triazaspiro[4.5]decane-6,8,10-trione **620965-89-1P**, 1-[6-[[1-(Pyridin-2-yl)-2,3,4,5-tetrahydro-1H-benzo[b]azepin-7-yl]oxy]pyridin-3-yl]-1,7,9-triazaspiro[4.5]decane-6,8,10-trione **620965-90-4P**, 1-[6-[[1-(Pyridazin-3-yl)-2,3,4,5-tetrahydro-1H-benzo[b]azepin-7-yl]oxy]pyridin-3-yl]-1,7,9-triazaspiro[4.5]decane-6,8,10-trione **620965-91-5P**, 1-[6-[(1-Isopropyl-2,3,4,5-tetrahydro-1H-benzo[b]azepin-7-yl)oxy]pyridin-3-yl]-1,7,9-triazaspiro[4.5]decane-6,8,10-trione **620965-92-6P**, 1-[6-[[2-(p-Tolyl)-1,2,3,4-tetrahydroisoquinolin-6-yl]oxy]pyridin-3-yl]-1,7,9-triazaspiro[4.5]decane-6,8,10-trione **620965-93-7P**, 1-[6-[[1-(4-Methoxyphenyl)-2,3,4,5-tetrahydro-1H-benzo[b]azepin-7-yl]oxy]pyridin-3-yl]-1,7,9-triazaspiro[4.5]decane-6,8,10-trione **620965-94-8P**, 1-[6-[[2-(4-Chlorophenyl)-1,2,3,4-tetrahydroisoquinolin-6-yl]oxy]pyridin-3-yl]-1,7,9-triazaspiro[4.5]decane-6,8,10-trione **620965-95-9P**, 4-[6-[[5-(6,8,10-Trioxo-1,7,9-triazaspiro[4.5]dec-1-yl)pyridin-2-yl]oxy]-3,4-dihydro-1H-isoquinolin-2-yl]benzonitrile **620965-96-0P**, 4-[5-[[5-(6,8,10-Trioxo-1,7,9-triazaspiro[4.5]dec-1-yl)pyridin-2-yl]oxy]-2,3-dihydroindol-1-yl]benzonitrile **620965-97-1P**, 1-[6-[[1-(4-Methoxyphenyl)-1H-benzimidazol-5-yl]oxy]pyridin-3-yl]-1,7,9-triazaspiro[4.5]decane-6,8,10-trione **620965-98-2P**, 1-[6-[[2-(4-Methoxyphenyl)-1,2,3,4-tetrahydroisoquinolin-6-yl]oxy]pyridin-3-yl]-1,7,9-triazaspiro[4.5]decane-6,8,10-trione **620965-99-3P**, 4-[6-[[5-(6,8,10-Trioxo-1,7,9-triazaspiro[4.5]dec-1-yl)pyridin-2-yl]oxy]-3,4-dihydro-2H-quinolin-1-yl]benzonitrile **620966-00-9P**, 1-[6-[[1-(4-Methoxyphenyl)-1,2,3,4-tetrahydroquinolin-6-yl]oxy]pyridin-3-yl]-1,7,9-triazaspiro[4.5]decane-6,8,10-trione **620966-01-0P**, 4-[7-[[5-(6,8,10-Trioxo-1,7,9-triazaspiro[4.5]dec-1-yl)pyridin-2-yl]oxy]-2,3,4,5-tetrahydrobenzo[b]azepin-1-yl]benzonitrile **620966-02-1P**, 4-[5-[[5-(6,8,10-Trioxo-1,7,9-triazaspiro[4.5]dec-1-yl)pyridin-2-yl]oxy]-

1,3-dihydroisoindol-2-yl]benzonitrile **620966-03-2P**,
1-[6-[[1-(4-Chlorophenyl)-1,2,3,4-tetrahydroquinolin-6-yl]oxy]pyridin-3-yl]-1,7,9-triazaspiro[4.5]decane-6,8,10-trione **620966-04-3P**,
1-[6-[[1-(p-Tolyl)-1,2,3,4-tetrahydroquinolin-6-yl]oxy]pyridin-3-yl]-1,7,9-triazaspiro[4.5]decane-6,8,10-trione **620966-05-4P**,
4-[5-[[5-(6,8,10-Trioxo-1,7,9-triazaspiro[4.5]dec-1-yl)pyridin-2-yl]oxy]benzimidazol-1-yl]benzonitrile **620966-06-5P**,
1-[6-[[1-(3-Methoxypropyl)-2,3,4,5-tetrahydro-1H-benzo[b]azepin-7-yl]oxy]pyridin-3-yl]-1,7,9-triazaspiro[4.5]decane-6,8,10-trione **620966-07-6P**, 1-[6-[[1-(4-Chlorophenyl)-2,3,4,5-tetrahydro-1H-benzo[b]azepin-7-yl]oxy]pyridin-3-yl]-1,7,9-triazaspiro[4.5]decane-6,8,10-trione **620966-08-7P**, 1-[6-[[1-(p-Tolyl)-2,3,4,5-tetrahydro-1H-benzo[b]azepin-7-yl]oxy]pyridin-3-yl]-1,7,9-triazaspiro[4.5]decane-6,8,10-trione **620966-09-8P**, 1-[6-[[2-(4-Methoxyphenyl)-2,3-dihydro-1H-isoindol-5-yl]oxy]pyridin-3-yl]-1,7,9-triazaspiro[4.5]decane-6,8,10-trione **620966-10-1P**, 1-[6-[[1-(Pyridazin-3-yl)-1,2,3,4-tetrahydroquinolin-6-yl]oxy]pyridin-3-yl]-1,7,9-triazaspiro[4.5]decane-6,8,10-trione **620966-11-2P**, 1-[6-[[1-(Pyridin-2-yl)-1,2,3,4-tetrahydroquinolin-6-yl]oxy]pyridin-3-yl]-1,7,9-triazaspiro[4.5]decane-6,8,10-trione **620966-12-3P**, 1-[6-[[1-(p-Tolyl)-1H-indazol-5-yl]oxy]pyridin-3-yl]-1,7,9-triazaspiro[4.5]decane-6,8,10-trione **620966-13-4P**,
1-[6-[[1-(4-Methoxyphenyl)-2,3-dihydro-1H-indol-5-yl]oxy]pyridin-3-yl]-1,7,9-triazaspiro[4.5]decane-6,8,10-trione **620966-14-5P**,
1-[6-[[1-(Pyridazin-3-yl)-1H-benzimidazol-5-yl]oxy]pyridin-3-yl]-1,7,9-triazaspiro[4.5]decane-6,8,10-trione **620966-15-6P**,
1-[6-[[1-(Pyridazin-3-yl)-2,3-dihydro-1H-indol-5-yl]oxy]pyridin-3-yl]-1,7,9-triazaspiro[4.5]decane-6,8,10-trione **620966-16-7P**,
1-[6-[[1-(Pyridazin-3-yl)-1H-indazol-5-yl]oxy]pyridin-3-yl]-1,7,9-triazaspiro[4.5]decane-6,8,10-trione **620966-17-8P**,
1-[6-[[1-(Pyridin-2-yl)-1H-benzimidazol-5-yl]oxy]pyridin-3-yl]-1,7,9-triazaspiro[4.5]decane-6,8,10-trione **620966-18-9P**,
1-[6-[[1-(Pyridin-2-yl)-2,3-dihydro-1H-indol-5-yl]oxy]pyridin-3-yl]-1,7,9-triazaspiro[4.5]decane-6,8,10-trione **620966-19-0P**,
1-[6-[[1-(Pyridin-2-yl)-1H-indazol-5-yl]oxy]pyridin-3-yl]-1,7,9-triazaspiro[4.5]decane-6,8,10-trione **620966-20-3P**,
1-[6-[[1-(4-Methoxyphenyl)-1H-indazol-5-yl]oxy]pyridin-3-yl]-1,7,9-triazaspiro[4.5]decane-6,8,10-trione **620966-21-4P**,
1-[6-[[1-(4-Chlorophenyl)-1H-benzimidazol-5-yl]oxy]pyridin-3-yl]-1,7,9-triazaspiro[4.5]decane-6,8,10-trione **620966-22-5P**,
1-[6-[[1-(3-Methoxypropyl)-1H-benzimidazol-5-yl]oxy]pyridin-3-yl]-1,7,9-triazaspiro[4.5]decane-6,8,10-trione **620966-23-6P**,
1-[6-[[1-(3-Methoxypropyl)-2,3-dihydro-1H-indol-5-yl]oxy]pyridin-3-yl]-1,7,9-triazaspiro[4.5]decane-6,8,10-trione **620966-24-7P**,
1-[6-[[1-(3-Methoxypropyl)-1H-indazol-5-yl]oxy]pyridin-3-yl]-1,7,9-triazaspiro[4.5]decane-6,8,10-trione **620966-25-8P**,
1-[6-[[1-(4-Chlorophenyl)-2,3-dihydro-1H-indol-5-yl]oxy]pyridin-3-yl]-1,7,9-triazaspiro[4.5]decane-6,8,10-trione **620966-26-9P**,
1-[6-[[1-(4-Chlorophenyl)-1H-indazol-5-yl]oxy]pyridin-3-yl]-1,7,9-triazaspiro[4.5]decane-6,8,10-trione **620966-27-0P**,
1-[6-[[1-(p-Tolyl)-1H-benzimidazol-5-yl]oxy]pyridin-3-yl]-1,7,9-triazaspiro[4.5]decane-6,8,10-trione **620966-28-1P**,
1-[6-[[1-(p-Tolyl)-2,3-dihydro-1H-indol-5-yl]oxy]pyridin-3-yl]-1,7,9-triazaspiro[4.5]decane-6,8,10-trione
RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(drug candidate; preparation of N-substituted-heteroaryloxy-aryl-spiro-pyrimidinetrione metalloproteinase inhibitors selective towards MMP-13)

RN 620965-06-2 CAPLUS
CN 1,7,9-Triazaspiro[4.5]decane-6,8,10-trione, 1-[6-[[1-(4-fluorophenyl)-1H-

indazol-5-yl]oxy]-3-pyridinyl]- (9CI) (CA INDEX NAME)



RN 620965-13-1 CAPLUS
CN Benzonitrile, 4-[5-[[5-(6,8,10-trioxo-1,7,9-triazaspiro[4.5]dec-1-yl)-2-pyridinyl]oxy]-1H-indazol-1-yl]- (9CI) (CA INDEX NAME)



RN 620965-19-7 CAPLUS
CN 1,7,9-Triazaspiro[4.5]decane-6,8,10-trione, 1-[6-[[1-(3-pyridinyl)-1H-indazol-5-yl]oxy]-3-pyridinyl]- (9CI) (CA INDEX NAME)



RN 620965-26-6 CAPLUS
CN 1,7,9-Triazaspiro[4.5]decane-6,8,10-trione, 1-[6-[(1-methyl-1H-indazol-5-yl)oxy]-3-pyridinyl]- (9CI) (CA INDEX NAME)



RN 620965-33-5 CAPLUS
CN 1,7,9-Triazaspiro[4.5]decane-6,8,10-trione, 1-[6-[[1-(1-methylethyl)-1H-indazol-5-yl]oxy]-3-pyridinyl]- (9CI) (CA INDEX NAME)



RN 620965-35-7 CAPLUS
CN 1,7,9-Triazaspiro[4.5]decane-6,8,10-trione, 1-[6-[[2-(1-methylethyl)-2H-indazol-5-yl]oxy]-3-pyridinyl]- (9CI) (CA INDEX NAME)



RN 620965-36-8 CAPLUS
CN Benzonitrile, 4-[1,3-dihydro-5-[[5-(6,8,10-trioxo-1,7,9-triazaspiro[4.5]dec-1-yl)-2-pyridinyl]oxy]-2H-indazol-2-yl]- (9CI) (CA INDEX NAME)



RN 620965-38-0 CAPLUS
CN 1,7,9-Triazaspiro[4.5]decane-6,8,10-trione, 1-[6-[[2,3-dihydro-2-(2-hydroxyethyl)-1-oxo-1H-isoindol-5-yl]oxy]-3-pyridinyl]- (9CI) (CA INDEX NAME)



RN 620965-39-1 CAPLUS
CN 1,7,9-Triazaspiro[4.5]decane-6,8,10-trione, 1-[6-[[2-(2-ethoxyethyl)-2,3-dihydro-1-oxo-1H-isoindol-5-yl]oxy]-3-pyridinyl]- (9CI) (CA INDEX NAME)



RN 620965-40-4 CAPLUS
CN 1,7,9-Triazaspiro[4.5]decane-6,8,10-trione, 1-[6-[[2-(4-fluorophenyl)-1,2,3,4-tetrahydro-6-isoquinolinyl]oxy]-3-pyridinyl]- (9CI) (CA INDEX NAME)

C:\Program Files\Stnexp\Queries\047592.str





chain nodes :
11 12 13 14 15 16 21
ring nodes :
1 2 3 4 5 6 7 8 9 10
chain bonds :
1-11 3-12 5-13 7-14 14-15 15-21 16-21
ring bonds :
1-2 1-6 2-3 3-4 4-5 4-7 4-10 5-6 7-8 8-9 9-10
exact/norm bonds :
1-2 1-6 1-11 2-3 3-4 3-12 4-5 4-7 4-10 5-6 5-13 7-8 7-14 8-9
9-10 14-15 15-21 16-21
isolated ring systems :
containing 1 :

G1:C,S

G2:C,N

G3:C,O,S,N

Match level :
1:Atom 2:Atom 3:Atom 4:Atom 5:Atom 6:Atom 7:Atom 8:Atom 9:Atom
10:Atom 11:CLASS 12:CLASS 13:CLASS 14:Atom 15:CLASS 16:Atom
21:CLASS



REFERENCE COUNT: 2 THERE ARE 2 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L3 ANSWER 3 OF 4 CAPLUS COPYRIGHT 2004 ACS on STN
ACCESSION NUMBER: 2003:875287 CAPLUS
DOCUMENT NUMBER: 139:364953
TITLE: Preparation of spirobarbituric acid derivatives useful as inhibitors of matrix metalloproteases
INVENTOR(S): Pitts, William J.; Kim, Soong-hoon; Barbosa, Joseph; Vaccaro, Wayne
PATENT ASSIGNEE(S): Bristol-Myers Squibb Company, USA
SOURCE: PCT Int. Appl., 75 pp.
CODEN: PIXXD2
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2003091252	A1	20031106	WO 2003-US12898	20030424
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NI, NO, NZ, OM, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM				
RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				
US 2004024001	A1	20040205	US 2003-423788	20030425

PRIORITY APPLN. INFO.: US 2002-375336P P 20020425
US 2002-428355P P 20021122

OTHER SOURCE(S): MARPAT 139:364953
GI

Not good

10/423,788



I



II

AB Spirobarbituric acids I [A, B, D = O, S; one of R1 and R2 = H, the other = H, alkyl, alkenyl; X = S, -S(O), SO, (un)substituted NH; G1 = CO, (un)substituted CH2, NH, CH:, N:; G2 = O, CO, (un)substituted CH2, NH, N:, CH:, :N, :CH; G# = (un)substituted CH2, NH, N:, CH:, :CH, :N; G4 = bond, (un)substituted CH2, CH2CH2, :CH] were prepared for use as inhibitors of MMPs, particularly MMP-13, aggrecanase, and/or TACE (no data). Thus, 4-BrC6H4NH2 was treated with BrCH(CO2Et)2 to give 4-BrC6H4NHCH(CO2Et)2 which was cyclized to 1-(4-bromophenyl)-5,5-diethoxycarbonylpyrrolidin-2-one which was treated with urea to give the spirobrabiturate II.

IT **620628-27-5P**

RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)

(preparation of spirobarbituric acid derivs. useful as inhibitors of matrix metalloproteases)

RN 620628-27-5 CAPLUS

CN 1,7,9-Triazaspiro[4.5]decane-2,6,8,10-tetrone, 1-[4-(phenylmethoxy)phenyl]- (9CI) (CA INDEX NAME)



IT **620628-01-5P 620628-04-8P 620628-05-9P**
620628-06-0P 620628-08-2P 620628-09-3P
620628-10-6P 620628-11-7P 620628-12-8P
620628-13-9P 620628-14-0P 620628-15-1P
620628-16-2P 620628-17-3P 620628-18-4P
620628-19-5P 620628-20-8P 620628-21-9P
620628-22-0P 620628-23-1P

RL: SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)

(preparation of spirobarbituric acid derivs. useful as inhibitors of matrix metalloproteases)

RN 620628-01-5 CAPLUS

CN 1,7,9-Triazaspiro[4.5]decane-2,6,8,10-tetrone, 1-[1,1'-biphenyl]-4-yl- (9CI) (CA INDEX NAME)



RN 620628-04-8 CAPLUS
CN 1,7,9-Triazaspiro[4.5]decane-2,6,8,10-tetrone, 1-[4-[4-(methylthio)phenoxy]phenyl]- (9CI) (CA INDEX NAME)



RN 620628-05-9 CAPLUS
CN 1,7,9-Triazaspiro[4.5]decane-2,6,8,10-tetrone, 3-methyl-1-(4-phenoxyphenyl)- (9CI) (CA INDEX NAME)



RN 620628-06-0 CAPLUS
CN 1,7,9-Triazaspiro[4.5]decane-2,6,8,10-tetrone, 4-ethyl-1-(4-phenoxyphenyl)-, (4R)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 620628-08-2 CAPLUS
CN 1,7,9-Triazaspiro[4.5]decane-2,6,8,10-tetrone, 1-[4-[(4-phenoxyphenyl)amino]phenyl]- (9CI) (CA INDEX NAME)



RN 620628-09-3 CAPLUS
CN Benzoic acid, 4-[4-(2,6,8,10-tetraoxo-1,7,9-triazaspiro[4.5]dec-1-yl)phenoxy]-, methyl ester (9CI) (CA INDEX NAME)



RN 620628-10-6 CAPLUS
CN Benzoic acid, 4-[4-(2,6,8,10-tetraoxo-1,7,9-triazaspiro[4.5]dec-1-yl)phenoxy]- (9CI) (CA INDEX NAME)



RN 620628-11-7 CAPLUS
CN 1,7,9-Triazaspiro[4.5]decane-2,6,8,10-tetrone, 1-[4-(4-dibenzofuranyloxy)phenyl]- (9CI) (CA INDEX NAME)



RN 620628-12-8 CAPLUS
CN 1,7,9-Triazaspiro[4.5]decane-2,6,8,10-tetrone, 1-[4-(2-methoxyphenoxy)phenyl]- (9CI) (CA INDEX NAME)



RN 620628-13-9 CAPLUS
CN 1,7,9-Triazaspiro[4.5]decane-2,6,8,10-tetrone, 1-[4-(3-methoxyphenoxy)phenyl]- (9CI) (CA INDEX NAME)



RN 620628-14-0 CAPLUS
CN 1,7,9-Triazaspiro[4.5]decane-2,6,8,10-tetrone, 1-[4-[4-(trifluoromethoxy)phenoxy]phenyl]- (9CI) (CA INDEX NAME)



RN 620628-15-1 CAPLUS
CN 1,7,9-Triazaspiro[4.5]decane-2,6,8,10-tetrone, 1-[4-(4-acetylphenoxy)phenyl]- (9CI) (CA INDEX NAME)



RN 620628-16-2 CAPLUS
CN 1,7,9-Triazaspiro[4.5]decane-2,6,8,10-tetrone, 1-[4-[(6-methoxy-3-pyridinyl)oxy]phenyl]- (9CI) (CA INDEX NAME)



RN 620628-17-3 CAPLUS
CN 1,7,9-Triazaspiro[4.5]decane-2,6,8,10-tetrone, 1-[4-(3-nitrophenoxy)phenyl]- (9CI) (CA INDEX NAME)



RN 620628-18-4 CAPLUS
CN 1,7,9-Triazaspiro[4.5]decane-2,6,8,10-tetrone, 1-[4-[4-(trifluoromethyl)phenoxy]phenyl]- (9CI) (CA INDEX NAME)



RN 620628-19-5 CAPLUS
CN 1,7,9-Triazaspiro[4.5]decane-2,6,8,10-tetrone, 1-[4-(4-phenoxyphenoxy)phenyl]- (9CI) (CA INDEX NAME)



RN 620628-20-8 CAPLUS
CN 1,7,9-Triazaspiro[4.5]decane-2,6,8,10-tetrone, 1-[4-[4-(methylsulfonyl)phenoxy]phenyl]- (9CI) (CA INDEX NAME)



RN 620628-21-9 CAPLUS
CN 1,7,9-Triazaspiro[4.5]decane-2,6,8,10-tetrone, 1-[4-(4-ethenylphenoxy)phenyl]- (9CI) (CA INDEX NAME)



RN 620628-22-0 CAPLUS
CN 1,7,9-Triazaspiro[4.5]decane-2,6,8,10-tetrone, 1-[4-[(2-methyl-4-quinolinyl)methoxy]phenyl]- (9CI) (CA INDEX NAME)



RN 620628-23-1 CAPLUS
CN 1,7,9-Triazaspiro[4.5]decane-2,6,8,10-tetrone, 4-ethyl-1-(4-phenoxyphenyl)-, (4S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



REFERENCE COUNT: 2 THERE ARE 2 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L3 ANSWER 4 OF 4 CAPLUS COPYRIGHT 2004 ACS on STN
ACCESSION NUMBER: 2002:332195 CAPLUS
DOCUMENT NUMBER: 136:340695
TITLE: Preparation of 1-aryl-1,7,9-triazaspiro[4.5]decanetetraones and analogs as metalloproteinase inhibitors
INVENTOR(S): Bronk, Brian Scott; Noe, Mark Carl; Wythes, Martin James
PATENT ASSIGNEE(S): Pfizer Products Inc., USA
SOURCE: PCT Int. Appl., 75 pp.
CODEN: PIXXD2
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2002034753	A2	20020502	WO 2001-IB1986	20011023
WO 2002034753	A3	20020815		
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, PH, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM				
RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				
AU 2002010813	A5	20020506	AU 2002-10813	20011023
US 2003096803	A1	20030522	US 2001-47592	20011023
BR 2001014913	A	20030701	BR 2001-14913	20011023
EP 1332146	A2	20030806	EP 2001-978721	20011023
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR				
EE 200300196	A	20031015	EE 2003-196	20011023
BG 107653	A	20031231	BG 2003-107653	20030320
NO 2003001853	A	20030623	NO 2003-1853	20030424
HR 2003000332	A1	20030630	HR 2003-332	20030428

PRIORITY APPLN. INFO.: US 2000-243389P P 20001026
WO 2001-IB1986 W 20011023

prosecution case

OTHER SOURCE(S): MARPAT 136:340695

AB Title compds. were prepared Thus, 6-(4-bromophenoxy)pyridine-3-amine was cyclocondensed with BrCH(CO2Et)2 and BrCH2CH2COCl and the product cyclocondensed with (H2N)2CO to give 1-[6-(4-bromophenoxy)-3-pyridinyl]-1,7,9-triazaspiro[4.5]decane-2,6,8,10-tetraone. Data for biol. activity of title compds. were given.

IT **418760-71-1P 418760-72-2P 418760-74-4P**
418760-75-5P 418760-76-6P 418760-77-7P
418760-78-8P 418760-79-9P 418760-81-3P
418760-83-5P 418760-84-6P
RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(preparation of 1-aryl-1,7,9-triazaspiro[4.5]decanetetraones and analogs as metalloproteinase inhibitors)

RN 418760-71-1 CAPLUS

CN 1,7,9-Triazaspiro[4.5]decane-2,6,8,10-tetrone, 1-[6-(4-bromophenoxy)-3-pyridinyl]- (9CI) (CA INDEX NAME)



RN 418760-72-2 CAPLUS

CN 1,7,9-Triazaspiro[4.5]decane-2,6,8,10-tetrone, 1-[6-(4-fluorophenoxy)-3-pyridinyl]- (9CI) (CA INDEX NAME)



RN 418760-74-4 CAPLUS
CN Benzonitrile, 4-[[5-(2,6,8,10-tetraoxo-1,7,9-triazaspiro[4.5]dec-1-yl)-2-pyridinyl]oxy]- (9CI) (CA INDEX NAME)



RN 418760-75-5 CAPLUS
CN 1,7,9-Triazaspiro[4.5]decane-2,6,8,10-tetrone, 1-[6-[4-(1,3,4-oxadiazol-2-yl)phenoxy]-3-pyridinyl]- (9CI) (CA INDEX NAME)



RN 418760-76-6 CAPLUS
CN 1,7,9-Triazaspiro[4.5]decane-2,6,8,10-tetrone, 1-[6-(4-ethylphenoxy)-3-pyridinyl]- (9CI) (CA INDEX NAME)



RN 418760-77-7 CAPLUS
CN Acetamide, N-[[4-[[5-(2,6,8,10-tetraoxo-1,7,9-triazaspiro[4.5]dec-1-yl)-2-pyridinyl]oxy]phenyl]methyl]- (9CI) (CA INDEX NAME)



RN 418760-78-8 CAPLUS
CN Propanamide, N-[[4-[[5-(2,6,8,10-tetraoxo-1,7,9-triazaspiro[4.5]dec-1-yl)-2-pyridinyl]oxy]phenyl]methyl]- (9CI) (CA INDEX NAME)



RN 418760-79-9 CAPLUS
CN Butanamide, N-[[4-[[5-(2,6,8,10-tetraoxo-1,7,9-triazaspiro[4.5]dec-1-yl)-2-pyridinyl]oxy]phenyl]methyl]- (9CI) (CA INDEX NAME)



RN 418760-81-3 CAPLUS
CN Pentanamide, N-[[4-[[5-(2,6,8,10-tetraoxo-1,7,9-triazaspiro[4.5]dec-1-yl)-2-pyridinyl]oxy]phenyl]methyl]- (9CI) (CA INDEX NAME)



RN 418760-83-5 CAPLUS
CN Cyclobutanecarboxamide, N-[[4-[[5-(2,6,8,10-tetraoxo-1,7,9-triazaspiro[4.5]dec-1-yl)-2-pyridinyl]oxy]phenyl]methyl]- (9CI) (CA INDEX NAME)

PAGE 1-A



PAGE 2-A



RN 418760-84-6 CAPLUS
CN 1,7,9-Triazaspiro[4.5]decane-2,6,8,10-tetrone, 1-[6-[4-(1H-pyrazol-1-ylmethyl)phenoxy]-3-pyridinyl]- (9CI) (CA INDEX NAME)

PAGE 1-A



PAGE 2-A



=> file reg

COST IN U.S. DOLLARS	SINCE FILE ENTRY	TOTAL SESSION
FULL ESTIMATED COST	19.90	175.53

DISCOUNT AMOUNTS (FOR QUALIFYING ACCOUNTS)	SINCE FILE ENTRY	TOTAL SESSION
CA SUBSCRIBER PRICE	-2.77	-2.77

FILE 'REGISTRY' ENTERED AT 18:09:11 ON 07 MAY 2004

Property values tagged with IC are from the ZIC/VINITI data file provided by InfoChem.

STRUCTURE FILE UPDATES: 6 MAY 2004 HIGHEST RN 680568-77-8
DICTIONARY FILE UPDATES: 6 MAY 2004 HIGHEST RN 680568-77-8

10/047,592

TSCA INFORMATION NOW CURRENT THROUGH JANUARY 6, 2004

Please note that search-term pricing does apply when conducting SmartSELECT searches.

Crossover limits have been increased. See HELP CROSSOVER for details.

Experimental and calculated property data are now available. For more information enter HELP PROP at an arrow prompt in the file or refer to the file summary sheet on the web at:
http://www.cas.org/ONLINE/DBSS/registryss.html